A detailed history of D. E. Shaw & Co., Inc. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 111,227 shares of NUVB stock, worth $313,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111,227
Holding current value
$313,660
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $3.83 $139,306 - $231,975
-60,568 Reduced 35.26%
111,227 $255,000
Q2 2024

Aug 14, 2024

SELL
$2.58 - $3.69 $1.78 Million - $2.54 Million
-689,145 Reduced 80.05%
171,795 $501,000
Q1 2024

May 15, 2024

BUY
$1.46 - $3.97 $505,174 - $1.37 Million
346,010 Added 67.2%
860,940 $3.13 Million
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $429,080 - $683,847
446,959 Added 657.57%
514,930 $777,000
Q3 2023

Nov 14, 2023

SELL
$1.26 - $2.1 $55,773 - $92,956
-44,265 Reduced 39.44%
67,971 $91,000
Q2 2023

Aug 14, 2023

BUY
$1.56 - $1.84 $50,754 - $59,864
32,535 Added 40.82%
112,236 $202,000
Q1 2023

May 15, 2023

SELL
$1.6 - $2.48 $61,712 - $95,653
-38,570 Reduced 32.61%
79,701 $132,000
Q4 2022

Feb 14, 2023

SELL
$1.68 - $2.5 $168,930 - $251,385
-100,554 Reduced 45.95%
118,271 $227,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $20,621 - $287,284
71,110 Added 48.14%
218,825 $490,000
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $372,395 - $672,381
114,937 Added 350.65%
147,715 $479,000
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $171,083 - $328,405
-37,192 Reduced 53.15%
32,778 $172,000
Q4 2021

Feb 14, 2022

SELL
$7.75 - $10.05 $740,287 - $959,986
-95,521 Reduced 57.72%
69,970 $595,000
Q3 2021

Nov 15, 2021

SELL
$7.78 - $10.0 $26,638 - $34,240
-3,424 Reduced 2.03%
165,491 $1.65 Million
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $1.56 Million - $2.45 Million
168,915 New
168,915 $1.57 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $613M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.